Therapeutic Value of Hyperthermic Intraperitoneal Chemotherapy on Non-radical Appendiceal Low-grade Pseudomyxoma Peritonei
Objective To explore the application value of hyperthermic intraperitoneal chemotherapy(HIPEC) on non-radical appendiceal low-grade pseudomyxoma peritonei(PMP). Methods We retrospectively analyzed the clinical data of 300 patients with non-radical appendiceal-origin low-grade PMP, and the prognostic...
Ausführliche Beschreibung
Gespeichert in:
| Autor*in: |
SHI Guanjun [verfasserIn] XIA Ao [verfasserIn] AN Lubiao [verfasserIn] ZHAI Xichao [verfasserIn] MA Ruiqing [verfasserIn] LU Yiyan [verfasserIn] PANG Shaojun [verfasserIn] CAI Ying [verfasserIn] WANG Bing [verfasserIn] CHEN Feng [verfasserIn] XU Hongbin [verfasserIn] |
|---|
| Format: |
E-Artikel |
|---|---|
| Sprache: |
Chinesisch |
| Erschienen: |
2020 |
|---|
| Schlagwörter: |
|---|
| Übergeordnetes Werk: |
In: Zhongliu Fangzhi Yanjiu - Magazine House of Cancer Research on Prevention and Treatment, 2019, 47(2020), 10, Seite 766-770 |
|---|---|
| Übergeordnetes Werk: |
volume:47 ; year:2020 ; number:10 ; pages:766-770 |
| Links: |
Link aufrufen |
|---|
| DOI / URN: |
10.3971/j.issn.1000-8578.2020.20.0012 |
|---|
| Katalog-ID: |
DOAJ055617506 |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | DOAJ055617506 | ||
| 003 | DE-627 | ||
| 005 | 20230308192440.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 230227s2020 xx |||||o 00| ||chi c | ||
| 024 | 7 | |a 10.3971/j.issn.1000-8578.2020.20.0012 |2 doi | |
| 035 | |a (DE-627)DOAJ055617506 | ||
| 035 | |a (DE-599)DOAJcb27f048011c42cc9a7694420201a772 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a chi | ||
| 050 | 0 | |a RC254-282 | |
| 100 | 0 | |a SHI Guanjun |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Therapeutic Value of Hyperthermic Intraperitoneal Chemotherapy on Non-radical Appendiceal Low-grade Pseudomyxoma Peritonei |
| 264 | 1 | |c 2020 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a Computermedien |b c |2 rdamedia | ||
| 338 | |a Online-Ressource |b cr |2 rdacarrier | ||
| 520 | |a Objective To explore the application value of hyperthermic intraperitoneal chemotherapy(HIPEC) on non-radical appendiceal low-grade pseudomyxoma peritonei(PMP). Methods We retrospectively analyzed the clinical data of 300 patients with non-radical appendiceal-origin low-grade PMP, and the prognostic factors and therapeutic value of HIPEC. Results The 10-year overall survival(OS) of 237 cases treated with HIPEC was significantly higher than that without HIPEC (52% vs. 26%, P < 0.001); the 10-year OS of the patients treated with intra- and post-operative HIPEC was also significantly higher than that with intraoperative HIPEC (57% vs. 44%, P=0.004). Univariate analysis showed that HIPEC, radical degree, PCI < 30 before tumor reduction, PCI < 30 after tumor reduction and CA199 abnormality were prognostic factors. Multivariate analysis showed that without HIPEC and CA125 abnormality were independent risk factors for poor prognosis. Conclusion For appendiceal low-grade PMP patients who cannot achieve complete cytoreduction, palliative maximal cytoreductive combined with HIPEC could significantly improve the long-term prognosis. | ||
| 650 | 4 | |a hyperthermia intraperitoneal chemotherapy | |
| 650 | 4 | |a pseudomyxoma peritonei(pmp) | |
| 650 | 4 | |a low-grade | |
| 650 | 4 | |a non-radical resection | |
| 650 | 4 | |a maximal cytoreductive | |
| 653 | 0 | |a Neoplasms. Tumors. Oncology. Including cancer and carcinogens | |
| 700 | 0 | |a XIA Ao |e verfasserin |4 aut | |
| 700 | 0 | |a AN Lubiao |e verfasserin |4 aut | |
| 700 | 0 | |a ZHAI Xichao |e verfasserin |4 aut | |
| 700 | 0 | |a MA Ruiqing |e verfasserin |4 aut | |
| 700 | 0 | |a LU Yiyan |e verfasserin |4 aut | |
| 700 | 0 | |a PANG Shaojun |e verfasserin |4 aut | |
| 700 | 0 | |a CAI Ying |e verfasserin |4 aut | |
| 700 | 0 | |a WANG Bing |e verfasserin |4 aut | |
| 700 | 0 | |a CHEN Feng |e verfasserin |4 aut | |
| 700 | 0 | |a XU Hongbin |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i In |t Zhongliu Fangzhi Yanjiu |d Magazine House of Cancer Research on Prevention and Treatment, 2019 |g 47(2020), 10, Seite 766-770 |w (DE-627)176063638X |x 10008578 |7 nnns |
| 773 | 1 | 8 | |g volume:47 |g year:2020 |g number:10 |g pages:766-770 |
| 856 | 4 | 0 | |u https://doi.org/10.3971/j.issn.1000-8578.2020.20.0012 |z kostenfrei |
| 856 | 4 | 0 | |u https://doaj.org/article/cb27f048011c42cc9a7694420201a772 |z kostenfrei |
| 856 | 4 | 0 | |u http://html.rhhz.net/ZLFZYJ/html/8578.2020.20.0012.htm |z kostenfrei |
| 856 | 4 | 2 | |u https://doaj.org/toc/1000-8578 |y Journal toc |z kostenfrei |
| 856 | 4 | 2 | |u https://doaj.org/toc/1000-8578 |y Journal toc |z kostenfrei |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a SYSFLAG_A | ||
| 912 | |a GBV_DOAJ | ||
| 951 | |a AR | ||
| 952 | |d 47 |j 2020 |e 10 |h 766-770 | ||
| author_variant |
s g sg x a xa a l al z x zx m r mr l y ly p s ps c y cy w b wb c f cf x h xh |
|---|---|
| matchkey_str |
article:10008578:2020----::hrpuivlefyetemcnrprtnaceohrponnaiaapniel |
| hierarchy_sort_str |
2020 |
| callnumber-subject-code |
RC |
| publishDate |
2020 |
| allfields |
10.3971/j.issn.1000-8578.2020.20.0012 doi (DE-627)DOAJ055617506 (DE-599)DOAJcb27f048011c42cc9a7694420201a772 DE-627 ger DE-627 rakwb chi RC254-282 SHI Guanjun verfasserin aut Therapeutic Value of Hyperthermic Intraperitoneal Chemotherapy on Non-radical Appendiceal Low-grade Pseudomyxoma Peritonei 2020 Text txt rdacontent Computermedien c rdamedia Online-Ressource cr rdacarrier Objective To explore the application value of hyperthermic intraperitoneal chemotherapy(HIPEC) on non-radical appendiceal low-grade pseudomyxoma peritonei(PMP). Methods We retrospectively analyzed the clinical data of 300 patients with non-radical appendiceal-origin low-grade PMP, and the prognostic factors and therapeutic value of HIPEC. Results The 10-year overall survival(OS) of 237 cases treated with HIPEC was significantly higher than that without HIPEC (52% vs. 26%, P < 0.001); the 10-year OS of the patients treated with intra- and post-operative HIPEC was also significantly higher than that with intraoperative HIPEC (57% vs. 44%, P=0.004). Univariate analysis showed that HIPEC, radical degree, PCI < 30 before tumor reduction, PCI < 30 after tumor reduction and CA199 abnormality were prognostic factors. Multivariate analysis showed that without HIPEC and CA125 abnormality were independent risk factors for poor prognosis. Conclusion For appendiceal low-grade PMP patients who cannot achieve complete cytoreduction, palliative maximal cytoreductive combined with HIPEC could significantly improve the long-term prognosis. hyperthermia intraperitoneal chemotherapy pseudomyxoma peritonei(pmp) low-grade non-radical resection maximal cytoreductive Neoplasms. Tumors. Oncology. Including cancer and carcinogens XIA Ao verfasserin aut AN Lubiao verfasserin aut ZHAI Xichao verfasserin aut MA Ruiqing verfasserin aut LU Yiyan verfasserin aut PANG Shaojun verfasserin aut CAI Ying verfasserin aut WANG Bing verfasserin aut CHEN Feng verfasserin aut XU Hongbin verfasserin aut In Zhongliu Fangzhi Yanjiu Magazine House of Cancer Research on Prevention and Treatment, 2019 47(2020), 10, Seite 766-770 (DE-627)176063638X 10008578 nnns volume:47 year:2020 number:10 pages:766-770 https://doi.org/10.3971/j.issn.1000-8578.2020.20.0012 kostenfrei https://doaj.org/article/cb27f048011c42cc9a7694420201a772 kostenfrei http://html.rhhz.net/ZLFZYJ/html/8578.2020.20.0012.htm kostenfrei https://doaj.org/toc/1000-8578 Journal toc kostenfrei https://doaj.org/toc/1000-8578 Journal toc kostenfrei GBV_USEFLAG_A SYSFLAG_A GBV_DOAJ AR 47 2020 10 766-770 |
| spelling |
10.3971/j.issn.1000-8578.2020.20.0012 doi (DE-627)DOAJ055617506 (DE-599)DOAJcb27f048011c42cc9a7694420201a772 DE-627 ger DE-627 rakwb chi RC254-282 SHI Guanjun verfasserin aut Therapeutic Value of Hyperthermic Intraperitoneal Chemotherapy on Non-radical Appendiceal Low-grade Pseudomyxoma Peritonei 2020 Text txt rdacontent Computermedien c rdamedia Online-Ressource cr rdacarrier Objective To explore the application value of hyperthermic intraperitoneal chemotherapy(HIPEC) on non-radical appendiceal low-grade pseudomyxoma peritonei(PMP). Methods We retrospectively analyzed the clinical data of 300 patients with non-radical appendiceal-origin low-grade PMP, and the prognostic factors and therapeutic value of HIPEC. Results The 10-year overall survival(OS) of 237 cases treated with HIPEC was significantly higher than that without HIPEC (52% vs. 26%, P < 0.001); the 10-year OS of the patients treated with intra- and post-operative HIPEC was also significantly higher than that with intraoperative HIPEC (57% vs. 44%, P=0.004). Univariate analysis showed that HIPEC, radical degree, PCI < 30 before tumor reduction, PCI < 30 after tumor reduction and CA199 abnormality were prognostic factors. Multivariate analysis showed that without HIPEC and CA125 abnormality were independent risk factors for poor prognosis. Conclusion For appendiceal low-grade PMP patients who cannot achieve complete cytoreduction, palliative maximal cytoreductive combined with HIPEC could significantly improve the long-term prognosis. hyperthermia intraperitoneal chemotherapy pseudomyxoma peritonei(pmp) low-grade non-radical resection maximal cytoreductive Neoplasms. Tumors. Oncology. Including cancer and carcinogens XIA Ao verfasserin aut AN Lubiao verfasserin aut ZHAI Xichao verfasserin aut MA Ruiqing verfasserin aut LU Yiyan verfasserin aut PANG Shaojun verfasserin aut CAI Ying verfasserin aut WANG Bing verfasserin aut CHEN Feng verfasserin aut XU Hongbin verfasserin aut In Zhongliu Fangzhi Yanjiu Magazine House of Cancer Research on Prevention and Treatment, 2019 47(2020), 10, Seite 766-770 (DE-627)176063638X 10008578 nnns volume:47 year:2020 number:10 pages:766-770 https://doi.org/10.3971/j.issn.1000-8578.2020.20.0012 kostenfrei https://doaj.org/article/cb27f048011c42cc9a7694420201a772 kostenfrei http://html.rhhz.net/ZLFZYJ/html/8578.2020.20.0012.htm kostenfrei https://doaj.org/toc/1000-8578 Journal toc kostenfrei https://doaj.org/toc/1000-8578 Journal toc kostenfrei GBV_USEFLAG_A SYSFLAG_A GBV_DOAJ AR 47 2020 10 766-770 |
| allfields_unstemmed |
10.3971/j.issn.1000-8578.2020.20.0012 doi (DE-627)DOAJ055617506 (DE-599)DOAJcb27f048011c42cc9a7694420201a772 DE-627 ger DE-627 rakwb chi RC254-282 SHI Guanjun verfasserin aut Therapeutic Value of Hyperthermic Intraperitoneal Chemotherapy on Non-radical Appendiceal Low-grade Pseudomyxoma Peritonei 2020 Text txt rdacontent Computermedien c rdamedia Online-Ressource cr rdacarrier Objective To explore the application value of hyperthermic intraperitoneal chemotherapy(HIPEC) on non-radical appendiceal low-grade pseudomyxoma peritonei(PMP). Methods We retrospectively analyzed the clinical data of 300 patients with non-radical appendiceal-origin low-grade PMP, and the prognostic factors and therapeutic value of HIPEC. Results The 10-year overall survival(OS) of 237 cases treated with HIPEC was significantly higher than that without HIPEC (52% vs. 26%, P < 0.001); the 10-year OS of the patients treated with intra- and post-operative HIPEC was also significantly higher than that with intraoperative HIPEC (57% vs. 44%, P=0.004). Univariate analysis showed that HIPEC, radical degree, PCI < 30 before tumor reduction, PCI < 30 after tumor reduction and CA199 abnormality were prognostic factors. Multivariate analysis showed that without HIPEC and CA125 abnormality were independent risk factors for poor prognosis. Conclusion For appendiceal low-grade PMP patients who cannot achieve complete cytoreduction, palliative maximal cytoreductive combined with HIPEC could significantly improve the long-term prognosis. hyperthermia intraperitoneal chemotherapy pseudomyxoma peritonei(pmp) low-grade non-radical resection maximal cytoreductive Neoplasms. Tumors. Oncology. Including cancer and carcinogens XIA Ao verfasserin aut AN Lubiao verfasserin aut ZHAI Xichao verfasserin aut MA Ruiqing verfasserin aut LU Yiyan verfasserin aut PANG Shaojun verfasserin aut CAI Ying verfasserin aut WANG Bing verfasserin aut CHEN Feng verfasserin aut XU Hongbin verfasserin aut In Zhongliu Fangzhi Yanjiu Magazine House of Cancer Research on Prevention and Treatment, 2019 47(2020), 10, Seite 766-770 (DE-627)176063638X 10008578 nnns volume:47 year:2020 number:10 pages:766-770 https://doi.org/10.3971/j.issn.1000-8578.2020.20.0012 kostenfrei https://doaj.org/article/cb27f048011c42cc9a7694420201a772 kostenfrei http://html.rhhz.net/ZLFZYJ/html/8578.2020.20.0012.htm kostenfrei https://doaj.org/toc/1000-8578 Journal toc kostenfrei https://doaj.org/toc/1000-8578 Journal toc kostenfrei GBV_USEFLAG_A SYSFLAG_A GBV_DOAJ AR 47 2020 10 766-770 |
| allfieldsGer |
10.3971/j.issn.1000-8578.2020.20.0012 doi (DE-627)DOAJ055617506 (DE-599)DOAJcb27f048011c42cc9a7694420201a772 DE-627 ger DE-627 rakwb chi RC254-282 SHI Guanjun verfasserin aut Therapeutic Value of Hyperthermic Intraperitoneal Chemotherapy on Non-radical Appendiceal Low-grade Pseudomyxoma Peritonei 2020 Text txt rdacontent Computermedien c rdamedia Online-Ressource cr rdacarrier Objective To explore the application value of hyperthermic intraperitoneal chemotherapy(HIPEC) on non-radical appendiceal low-grade pseudomyxoma peritonei(PMP). Methods We retrospectively analyzed the clinical data of 300 patients with non-radical appendiceal-origin low-grade PMP, and the prognostic factors and therapeutic value of HIPEC. Results The 10-year overall survival(OS) of 237 cases treated with HIPEC was significantly higher than that without HIPEC (52% vs. 26%, P < 0.001); the 10-year OS of the patients treated with intra- and post-operative HIPEC was also significantly higher than that with intraoperative HIPEC (57% vs. 44%, P=0.004). Univariate analysis showed that HIPEC, radical degree, PCI < 30 before tumor reduction, PCI < 30 after tumor reduction and CA199 abnormality were prognostic factors. Multivariate analysis showed that without HIPEC and CA125 abnormality were independent risk factors for poor prognosis. Conclusion For appendiceal low-grade PMP patients who cannot achieve complete cytoreduction, palliative maximal cytoreductive combined with HIPEC could significantly improve the long-term prognosis. hyperthermia intraperitoneal chemotherapy pseudomyxoma peritonei(pmp) low-grade non-radical resection maximal cytoreductive Neoplasms. Tumors. Oncology. Including cancer and carcinogens XIA Ao verfasserin aut AN Lubiao verfasserin aut ZHAI Xichao verfasserin aut MA Ruiqing verfasserin aut LU Yiyan verfasserin aut PANG Shaojun verfasserin aut CAI Ying verfasserin aut WANG Bing verfasserin aut CHEN Feng verfasserin aut XU Hongbin verfasserin aut In Zhongliu Fangzhi Yanjiu Magazine House of Cancer Research on Prevention and Treatment, 2019 47(2020), 10, Seite 766-770 (DE-627)176063638X 10008578 nnns volume:47 year:2020 number:10 pages:766-770 https://doi.org/10.3971/j.issn.1000-8578.2020.20.0012 kostenfrei https://doaj.org/article/cb27f048011c42cc9a7694420201a772 kostenfrei http://html.rhhz.net/ZLFZYJ/html/8578.2020.20.0012.htm kostenfrei https://doaj.org/toc/1000-8578 Journal toc kostenfrei https://doaj.org/toc/1000-8578 Journal toc kostenfrei GBV_USEFLAG_A SYSFLAG_A GBV_DOAJ AR 47 2020 10 766-770 |
| allfieldsSound |
10.3971/j.issn.1000-8578.2020.20.0012 doi (DE-627)DOAJ055617506 (DE-599)DOAJcb27f048011c42cc9a7694420201a772 DE-627 ger DE-627 rakwb chi RC254-282 SHI Guanjun verfasserin aut Therapeutic Value of Hyperthermic Intraperitoneal Chemotherapy on Non-radical Appendiceal Low-grade Pseudomyxoma Peritonei 2020 Text txt rdacontent Computermedien c rdamedia Online-Ressource cr rdacarrier Objective To explore the application value of hyperthermic intraperitoneal chemotherapy(HIPEC) on non-radical appendiceal low-grade pseudomyxoma peritonei(PMP). Methods We retrospectively analyzed the clinical data of 300 patients with non-radical appendiceal-origin low-grade PMP, and the prognostic factors and therapeutic value of HIPEC. Results The 10-year overall survival(OS) of 237 cases treated with HIPEC was significantly higher than that without HIPEC (52% vs. 26%, P < 0.001); the 10-year OS of the patients treated with intra- and post-operative HIPEC was also significantly higher than that with intraoperative HIPEC (57% vs. 44%, P=0.004). Univariate analysis showed that HIPEC, radical degree, PCI < 30 before tumor reduction, PCI < 30 after tumor reduction and CA199 abnormality were prognostic factors. Multivariate analysis showed that without HIPEC and CA125 abnormality were independent risk factors for poor prognosis. Conclusion For appendiceal low-grade PMP patients who cannot achieve complete cytoreduction, palliative maximal cytoreductive combined with HIPEC could significantly improve the long-term prognosis. hyperthermia intraperitoneal chemotherapy pseudomyxoma peritonei(pmp) low-grade non-radical resection maximal cytoreductive Neoplasms. Tumors. Oncology. Including cancer and carcinogens XIA Ao verfasserin aut AN Lubiao verfasserin aut ZHAI Xichao verfasserin aut MA Ruiqing verfasserin aut LU Yiyan verfasserin aut PANG Shaojun verfasserin aut CAI Ying verfasserin aut WANG Bing verfasserin aut CHEN Feng verfasserin aut XU Hongbin verfasserin aut In Zhongliu Fangzhi Yanjiu Magazine House of Cancer Research on Prevention and Treatment, 2019 47(2020), 10, Seite 766-770 (DE-627)176063638X 10008578 nnns volume:47 year:2020 number:10 pages:766-770 https://doi.org/10.3971/j.issn.1000-8578.2020.20.0012 kostenfrei https://doaj.org/article/cb27f048011c42cc9a7694420201a772 kostenfrei http://html.rhhz.net/ZLFZYJ/html/8578.2020.20.0012.htm kostenfrei https://doaj.org/toc/1000-8578 Journal toc kostenfrei https://doaj.org/toc/1000-8578 Journal toc kostenfrei GBV_USEFLAG_A SYSFLAG_A GBV_DOAJ AR 47 2020 10 766-770 |
| language |
Chinese |
| source |
In Zhongliu Fangzhi Yanjiu 47(2020), 10, Seite 766-770 volume:47 year:2020 number:10 pages:766-770 |
| sourceStr |
In Zhongliu Fangzhi Yanjiu 47(2020), 10, Seite 766-770 volume:47 year:2020 number:10 pages:766-770 |
| format_phy_str_mv |
Article |
| institution |
findex.gbv.de |
| topic_facet |
hyperthermia intraperitoneal chemotherapy pseudomyxoma peritonei(pmp) low-grade non-radical resection maximal cytoreductive Neoplasms. Tumors. Oncology. Including cancer and carcinogens |
| isfreeaccess_bool |
true |
| container_title |
Zhongliu Fangzhi Yanjiu |
| authorswithroles_txt_mv |
SHI Guanjun @@aut@@ XIA Ao @@aut@@ AN Lubiao @@aut@@ ZHAI Xichao @@aut@@ MA Ruiqing @@aut@@ LU Yiyan @@aut@@ PANG Shaojun @@aut@@ CAI Ying @@aut@@ WANG Bing @@aut@@ CHEN Feng @@aut@@ XU Hongbin @@aut@@ |
| publishDateDaySort_date |
2020-01-01T00:00:00Z |
| hierarchy_top_id |
176063638X |
| id |
DOAJ055617506 |
| language_de |
chinesisch |
| fullrecord |
<?xml version="1.0" encoding="UTF-8"?><collection xmlns="http://www.loc.gov/MARC21/slim"><record><leader>01000caa a22002652 4500</leader><controlfield tag="001">DOAJ055617506</controlfield><controlfield tag="003">DE-627</controlfield><controlfield tag="005">20230308192440.0</controlfield><controlfield tag="007">cr uuu---uuuuu</controlfield><controlfield tag="008">230227s2020 xx |||||o 00| ||chi c</controlfield><datafield tag="024" ind1="7" ind2=" "><subfield code="a">10.3971/j.issn.1000-8578.2020.20.0012</subfield><subfield code="2">doi</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(DE-627)DOAJ055617506</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(DE-599)DOAJcb27f048011c42cc9a7694420201a772</subfield></datafield><datafield tag="040" ind1=" " ind2=" "><subfield code="a">DE-627</subfield><subfield code="b">ger</subfield><subfield code="c">DE-627</subfield><subfield code="e">rakwb</subfield></datafield><datafield tag="041" ind1=" " ind2=" "><subfield code="a">chi</subfield></datafield><datafield tag="050" ind1=" " ind2="0"><subfield code="a">RC254-282</subfield></datafield><datafield tag="100" ind1="0" ind2=" "><subfield code="a">SHI Guanjun</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="245" ind1="1" ind2="0"><subfield code="a">Therapeutic Value of Hyperthermic Intraperitoneal Chemotherapy on Non-radical Appendiceal Low-grade Pseudomyxoma Peritonei</subfield></datafield><datafield tag="264" ind1=" " ind2="1"><subfield code="c">2020</subfield></datafield><datafield tag="336" ind1=" " ind2=" "><subfield code="a">Text</subfield><subfield code="b">txt</subfield><subfield code="2">rdacontent</subfield></datafield><datafield tag="337" ind1=" " ind2=" "><subfield code="a">Computermedien</subfield><subfield code="b">c</subfield><subfield code="2">rdamedia</subfield></datafield><datafield tag="338" ind1=" " ind2=" "><subfield code="a">Online-Ressource</subfield><subfield code="b">cr</subfield><subfield code="2">rdacarrier</subfield></datafield><datafield tag="520" ind1=" " ind2=" "><subfield code="a">Objective To explore the application value of hyperthermic intraperitoneal chemotherapy(HIPEC) on non-radical appendiceal low-grade pseudomyxoma peritonei(PMP). Methods We retrospectively analyzed the clinical data of 300 patients with non-radical appendiceal-origin low-grade PMP, and the prognostic factors and therapeutic value of HIPEC. Results The 10-year overall survival(OS) of 237 cases treated with HIPEC was significantly higher than that without HIPEC (52% vs. 26%, P < 0.001); the 10-year OS of the patients treated with intra- and post-operative HIPEC was also significantly higher than that with intraoperative HIPEC (57% vs. 44%, P=0.004). Univariate analysis showed that HIPEC, radical degree, PCI < 30 before tumor reduction, PCI < 30 after tumor reduction and CA199 abnormality were prognostic factors. Multivariate analysis showed that without HIPEC and CA125 abnormality were independent risk factors for poor prognosis. Conclusion For appendiceal low-grade PMP patients who cannot achieve complete cytoreduction, palliative maximal cytoreductive combined with HIPEC could significantly improve the long-term prognosis.</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">hyperthermia intraperitoneal chemotherapy</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">pseudomyxoma peritonei(pmp)</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">low-grade</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">non-radical resection</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">maximal cytoreductive</subfield></datafield><datafield tag="653" ind1=" " ind2="0"><subfield code="a">Neoplasms. Tumors. Oncology. Including cancer and carcinogens</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">XIA Ao</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">AN Lubiao</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">ZHAI Xichao</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">MA Ruiqing</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">LU Yiyan</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">PANG Shaojun</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">CAI Ying</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">WANG Bing</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">CHEN Feng</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">XU Hongbin</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="773" ind1="0" ind2="8"><subfield code="i">In</subfield><subfield code="t">Zhongliu Fangzhi Yanjiu</subfield><subfield code="d">Magazine House of Cancer Research on Prevention and Treatment, 2019</subfield><subfield code="g">47(2020), 10, Seite 766-770</subfield><subfield code="w">(DE-627)176063638X</subfield><subfield code="x">10008578</subfield><subfield code="7">nnns</subfield></datafield><datafield tag="773" ind1="1" ind2="8"><subfield code="g">volume:47</subfield><subfield code="g">year:2020</subfield><subfield code="g">number:10</subfield><subfield code="g">pages:766-770</subfield></datafield><datafield tag="856" ind1="4" ind2="0"><subfield code="u">https://doi.org/10.3971/j.issn.1000-8578.2020.20.0012</subfield><subfield code="z">kostenfrei</subfield></datafield><datafield tag="856" ind1="4" ind2="0"><subfield code="u">https://doaj.org/article/cb27f048011c42cc9a7694420201a772</subfield><subfield code="z">kostenfrei</subfield></datafield><datafield tag="856" ind1="4" ind2="0"><subfield code="u">http://html.rhhz.net/ZLFZYJ/html/8578.2020.20.0012.htm</subfield><subfield code="z">kostenfrei</subfield></datafield><datafield tag="856" ind1="4" ind2="2"><subfield code="u">https://doaj.org/toc/1000-8578</subfield><subfield code="y">Journal toc</subfield><subfield code="z">kostenfrei</subfield></datafield><datafield tag="856" ind1="4" ind2="2"><subfield code="u">https://doaj.org/toc/1000-8578</subfield><subfield code="y">Journal toc</subfield><subfield code="z">kostenfrei</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_USEFLAG_A</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">SYSFLAG_A</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_DOAJ</subfield></datafield><datafield tag="951" ind1=" " ind2=" "><subfield code="a">AR</subfield></datafield><datafield tag="952" ind1=" " ind2=" "><subfield code="d">47</subfield><subfield code="j">2020</subfield><subfield code="e">10</subfield><subfield code="h">766-770</subfield></datafield></record></collection>
|
| callnumber-first |
R - Medicine |
| author |
SHI Guanjun |
| spellingShingle |
SHI Guanjun misc RC254-282 misc hyperthermia intraperitoneal chemotherapy misc pseudomyxoma peritonei(pmp) misc low-grade misc non-radical resection misc maximal cytoreductive misc Neoplasms. Tumors. Oncology. Including cancer and carcinogens Therapeutic Value of Hyperthermic Intraperitoneal Chemotherapy on Non-radical Appendiceal Low-grade Pseudomyxoma Peritonei |
| authorStr |
SHI Guanjun |
| ppnlink_with_tag_str_mv |
@@773@@(DE-627)176063638X |
| format |
electronic Article |
| delete_txt_mv |
keep |
| author_role |
aut aut aut aut aut aut aut aut aut aut aut |
| collection |
DOAJ |
| remote_str |
true |
| callnumber-label |
RC254-282 |
| illustrated |
Not Illustrated |
| issn |
10008578 |
| topic_title |
RC254-282 Therapeutic Value of Hyperthermic Intraperitoneal Chemotherapy on Non-radical Appendiceal Low-grade Pseudomyxoma Peritonei hyperthermia intraperitoneal chemotherapy pseudomyxoma peritonei(pmp) low-grade non-radical resection maximal cytoreductive |
| topic |
misc RC254-282 misc hyperthermia intraperitoneal chemotherapy misc pseudomyxoma peritonei(pmp) misc low-grade misc non-radical resection misc maximal cytoreductive misc Neoplasms. Tumors. Oncology. Including cancer and carcinogens |
| topic_unstemmed |
misc RC254-282 misc hyperthermia intraperitoneal chemotherapy misc pseudomyxoma peritonei(pmp) misc low-grade misc non-radical resection misc maximal cytoreductive misc Neoplasms. Tumors. Oncology. Including cancer and carcinogens |
| topic_browse |
misc RC254-282 misc hyperthermia intraperitoneal chemotherapy misc pseudomyxoma peritonei(pmp) misc low-grade misc non-radical resection misc maximal cytoreductive misc Neoplasms. Tumors. Oncology. Including cancer and carcinogens |
| format_facet |
Elektronische Aufsätze Aufsätze Elektronische Ressource |
| format_main_str_mv |
Text Zeitschrift/Artikel |
| carriertype_str_mv |
cr |
| hierarchy_parent_title |
Zhongliu Fangzhi Yanjiu |
| hierarchy_parent_id |
176063638X |
| hierarchy_top_title |
Zhongliu Fangzhi Yanjiu |
| isfreeaccess_txt |
true |
| familylinks_str_mv |
(DE-627)176063638X |
| title |
Therapeutic Value of Hyperthermic Intraperitoneal Chemotherapy on Non-radical Appendiceal Low-grade Pseudomyxoma Peritonei |
| ctrlnum |
(DE-627)DOAJ055617506 (DE-599)DOAJcb27f048011c42cc9a7694420201a772 |
| title_full |
Therapeutic Value of Hyperthermic Intraperitoneal Chemotherapy on Non-radical Appendiceal Low-grade Pseudomyxoma Peritonei |
| author_sort |
SHI Guanjun |
| journal |
Zhongliu Fangzhi Yanjiu |
| journalStr |
Zhongliu Fangzhi Yanjiu |
| callnumber-first-code |
R |
| lang_code |
chi |
| isOA_bool |
true |
| recordtype |
marc |
| publishDateSort |
2020 |
| contenttype_str_mv |
txt |
| container_start_page |
766 |
| author_browse |
SHI Guanjun XIA Ao AN Lubiao ZHAI Xichao MA Ruiqing LU Yiyan PANG Shaojun CAI Ying WANG Bing CHEN Feng XU Hongbin |
| container_volume |
47 |
| class |
RC254-282 |
| format_se |
Elektronische Aufsätze |
| author-letter |
SHI Guanjun |
| doi_str_mv |
10.3971/j.issn.1000-8578.2020.20.0012 |
| author2-role |
verfasserin |
| title_sort |
therapeutic value of hyperthermic intraperitoneal chemotherapy on non-radical appendiceal low-grade pseudomyxoma peritonei |
| callnumber |
RC254-282 |
| title_auth |
Therapeutic Value of Hyperthermic Intraperitoneal Chemotherapy on Non-radical Appendiceal Low-grade Pseudomyxoma Peritonei |
| abstract |
Objective To explore the application value of hyperthermic intraperitoneal chemotherapy(HIPEC) on non-radical appendiceal low-grade pseudomyxoma peritonei(PMP). Methods We retrospectively analyzed the clinical data of 300 patients with non-radical appendiceal-origin low-grade PMP, and the prognostic factors and therapeutic value of HIPEC. Results The 10-year overall survival(OS) of 237 cases treated with HIPEC was significantly higher than that without HIPEC (52% vs. 26%, P < 0.001); the 10-year OS of the patients treated with intra- and post-operative HIPEC was also significantly higher than that with intraoperative HIPEC (57% vs. 44%, P=0.004). Univariate analysis showed that HIPEC, radical degree, PCI < 30 before tumor reduction, PCI < 30 after tumor reduction and CA199 abnormality were prognostic factors. Multivariate analysis showed that without HIPEC and CA125 abnormality were independent risk factors for poor prognosis. Conclusion For appendiceal low-grade PMP patients who cannot achieve complete cytoreduction, palliative maximal cytoreductive combined with HIPEC could significantly improve the long-term prognosis. |
| abstractGer |
Objective To explore the application value of hyperthermic intraperitoneal chemotherapy(HIPEC) on non-radical appendiceal low-grade pseudomyxoma peritonei(PMP). Methods We retrospectively analyzed the clinical data of 300 patients with non-radical appendiceal-origin low-grade PMP, and the prognostic factors and therapeutic value of HIPEC. Results The 10-year overall survival(OS) of 237 cases treated with HIPEC was significantly higher than that without HIPEC (52% vs. 26%, P < 0.001); the 10-year OS of the patients treated with intra- and post-operative HIPEC was also significantly higher than that with intraoperative HIPEC (57% vs. 44%, P=0.004). Univariate analysis showed that HIPEC, radical degree, PCI < 30 before tumor reduction, PCI < 30 after tumor reduction and CA199 abnormality were prognostic factors. Multivariate analysis showed that without HIPEC and CA125 abnormality were independent risk factors for poor prognosis. Conclusion For appendiceal low-grade PMP patients who cannot achieve complete cytoreduction, palliative maximal cytoreductive combined with HIPEC could significantly improve the long-term prognosis. |
| abstract_unstemmed |
Objective To explore the application value of hyperthermic intraperitoneal chemotherapy(HIPEC) on non-radical appendiceal low-grade pseudomyxoma peritonei(PMP). Methods We retrospectively analyzed the clinical data of 300 patients with non-radical appendiceal-origin low-grade PMP, and the prognostic factors and therapeutic value of HIPEC. Results The 10-year overall survival(OS) of 237 cases treated with HIPEC was significantly higher than that without HIPEC (52% vs. 26%, P < 0.001); the 10-year OS of the patients treated with intra- and post-operative HIPEC was also significantly higher than that with intraoperative HIPEC (57% vs. 44%, P=0.004). Univariate analysis showed that HIPEC, radical degree, PCI < 30 before tumor reduction, PCI < 30 after tumor reduction and CA199 abnormality were prognostic factors. Multivariate analysis showed that without HIPEC and CA125 abnormality were independent risk factors for poor prognosis. Conclusion For appendiceal low-grade PMP patients who cannot achieve complete cytoreduction, palliative maximal cytoreductive combined with HIPEC could significantly improve the long-term prognosis. |
| collection_details |
GBV_USEFLAG_A SYSFLAG_A GBV_DOAJ |
| container_issue |
10 |
| title_short |
Therapeutic Value of Hyperthermic Intraperitoneal Chemotherapy on Non-radical Appendiceal Low-grade Pseudomyxoma Peritonei |
| url |
https://doi.org/10.3971/j.issn.1000-8578.2020.20.0012 https://doaj.org/article/cb27f048011c42cc9a7694420201a772 http://html.rhhz.net/ZLFZYJ/html/8578.2020.20.0012.htm https://doaj.org/toc/1000-8578 |
| remote_bool |
true |
| author2 |
XIA Ao AN Lubiao ZHAI Xichao MA Ruiqing LU Yiyan PANG Shaojun CAI Ying WANG Bing CHEN Feng XU Hongbin |
| author2Str |
XIA Ao AN Lubiao ZHAI Xichao MA Ruiqing LU Yiyan PANG Shaojun CAI Ying WANG Bing CHEN Feng XU Hongbin |
| ppnlink |
176063638X |
| callnumber-subject |
RC - Internal Medicine |
| mediatype_str_mv |
c |
| isOA_txt |
true |
| hochschulschrift_bool |
false |
| doi_str |
10.3971/j.issn.1000-8578.2020.20.0012 |
| callnumber-a |
RC254-282 |
| up_date |
2024-07-03T16:02:59.627Z |
| _version_ |
1803574396454961152 |
| fullrecord_marcxml |
<?xml version="1.0" encoding="UTF-8"?><collection xmlns="http://www.loc.gov/MARC21/slim"><record><leader>01000caa a22002652 4500</leader><controlfield tag="001">DOAJ055617506</controlfield><controlfield tag="003">DE-627</controlfield><controlfield tag="005">20230308192440.0</controlfield><controlfield tag="007">cr uuu---uuuuu</controlfield><controlfield tag="008">230227s2020 xx |||||o 00| ||chi c</controlfield><datafield tag="024" ind1="7" ind2=" "><subfield code="a">10.3971/j.issn.1000-8578.2020.20.0012</subfield><subfield code="2">doi</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(DE-627)DOAJ055617506</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(DE-599)DOAJcb27f048011c42cc9a7694420201a772</subfield></datafield><datafield tag="040" ind1=" " ind2=" "><subfield code="a">DE-627</subfield><subfield code="b">ger</subfield><subfield code="c">DE-627</subfield><subfield code="e">rakwb</subfield></datafield><datafield tag="041" ind1=" " ind2=" "><subfield code="a">chi</subfield></datafield><datafield tag="050" ind1=" " ind2="0"><subfield code="a">RC254-282</subfield></datafield><datafield tag="100" ind1="0" ind2=" "><subfield code="a">SHI Guanjun</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="245" ind1="1" ind2="0"><subfield code="a">Therapeutic Value of Hyperthermic Intraperitoneal Chemotherapy on Non-radical Appendiceal Low-grade Pseudomyxoma Peritonei</subfield></datafield><datafield tag="264" ind1=" " ind2="1"><subfield code="c">2020</subfield></datafield><datafield tag="336" ind1=" " ind2=" "><subfield code="a">Text</subfield><subfield code="b">txt</subfield><subfield code="2">rdacontent</subfield></datafield><datafield tag="337" ind1=" " ind2=" "><subfield code="a">Computermedien</subfield><subfield code="b">c</subfield><subfield code="2">rdamedia</subfield></datafield><datafield tag="338" ind1=" " ind2=" "><subfield code="a">Online-Ressource</subfield><subfield code="b">cr</subfield><subfield code="2">rdacarrier</subfield></datafield><datafield tag="520" ind1=" " ind2=" "><subfield code="a">Objective To explore the application value of hyperthermic intraperitoneal chemotherapy(HIPEC) on non-radical appendiceal low-grade pseudomyxoma peritonei(PMP). Methods We retrospectively analyzed the clinical data of 300 patients with non-radical appendiceal-origin low-grade PMP, and the prognostic factors and therapeutic value of HIPEC. Results The 10-year overall survival(OS) of 237 cases treated with HIPEC was significantly higher than that without HIPEC (52% vs. 26%, P < 0.001); the 10-year OS of the patients treated with intra- and post-operative HIPEC was also significantly higher than that with intraoperative HIPEC (57% vs. 44%, P=0.004). Univariate analysis showed that HIPEC, radical degree, PCI < 30 before tumor reduction, PCI < 30 after tumor reduction and CA199 abnormality were prognostic factors. Multivariate analysis showed that without HIPEC and CA125 abnormality were independent risk factors for poor prognosis. Conclusion For appendiceal low-grade PMP patients who cannot achieve complete cytoreduction, palliative maximal cytoreductive combined with HIPEC could significantly improve the long-term prognosis.</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">hyperthermia intraperitoneal chemotherapy</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">pseudomyxoma peritonei(pmp)</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">low-grade</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">non-radical resection</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">maximal cytoreductive</subfield></datafield><datafield tag="653" ind1=" " ind2="0"><subfield code="a">Neoplasms. Tumors. Oncology. Including cancer and carcinogens</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">XIA Ao</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">AN Lubiao</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">ZHAI Xichao</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">MA Ruiqing</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">LU Yiyan</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">PANG Shaojun</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">CAI Ying</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">WANG Bing</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">CHEN Feng</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">XU Hongbin</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="773" ind1="0" ind2="8"><subfield code="i">In</subfield><subfield code="t">Zhongliu Fangzhi Yanjiu</subfield><subfield code="d">Magazine House of Cancer Research on Prevention and Treatment, 2019</subfield><subfield code="g">47(2020), 10, Seite 766-770</subfield><subfield code="w">(DE-627)176063638X</subfield><subfield code="x">10008578</subfield><subfield code="7">nnns</subfield></datafield><datafield tag="773" ind1="1" ind2="8"><subfield code="g">volume:47</subfield><subfield code="g">year:2020</subfield><subfield code="g">number:10</subfield><subfield code="g">pages:766-770</subfield></datafield><datafield tag="856" ind1="4" ind2="0"><subfield code="u">https://doi.org/10.3971/j.issn.1000-8578.2020.20.0012</subfield><subfield code="z">kostenfrei</subfield></datafield><datafield tag="856" ind1="4" ind2="0"><subfield code="u">https://doaj.org/article/cb27f048011c42cc9a7694420201a772</subfield><subfield code="z">kostenfrei</subfield></datafield><datafield tag="856" ind1="4" ind2="0"><subfield code="u">http://html.rhhz.net/ZLFZYJ/html/8578.2020.20.0012.htm</subfield><subfield code="z">kostenfrei</subfield></datafield><datafield tag="856" ind1="4" ind2="2"><subfield code="u">https://doaj.org/toc/1000-8578</subfield><subfield code="y">Journal toc</subfield><subfield code="z">kostenfrei</subfield></datafield><datafield tag="856" ind1="4" ind2="2"><subfield code="u">https://doaj.org/toc/1000-8578</subfield><subfield code="y">Journal toc</subfield><subfield code="z">kostenfrei</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_USEFLAG_A</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">SYSFLAG_A</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_DOAJ</subfield></datafield><datafield tag="951" ind1=" " ind2=" "><subfield code="a">AR</subfield></datafield><datafield tag="952" ind1=" " ind2=" "><subfield code="d">47</subfield><subfield code="j">2020</subfield><subfield code="e">10</subfield><subfield code="h">766-770</subfield></datafield></record></collection>
|
| score |
7.401704 |